Benzodiazepines in clinical practice: Consideration of their long-term use and alternative agents

Journal of Clinical Psychiatry

Volumn 66, Issue SUPPL. 2, 2005, Pages 21-27

  Stevens, Julie C ^a   Pollack, Mark H ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPRAZOLAM; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; BUSPIRONE; CHLORPROMAZINE; CLONAZEPAM; DIAZEPAM; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; LORAZEPAM; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; NEUROTROPHIC FACTOR; PRAZOSIN; PROPRANOLOL; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TEMAZEPAM; THIORIDAZINE; TIAGABINE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT;

ANXIETY DISORDER; ATAXIA; CHRONIC DRUG ADMINISTRATION; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITIVE DEFECT; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG TOLERANCE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LOW DRUG DOSE; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; PSYCHOPHARMACOTHERAPY; REVIEW; SEDATION; SIDE EFFECT; TARDIVE DYSKINESIA; TRANQUILIZING ACTIVITY;

ANTI-ANXIETY AGENTS; ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; ANXIETY DISORDERS; BENZODIAZEPINES; COGNITION DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG TOLERANCE; GAMMA-AMINOBUTYRIC ACID; HUMANS; LONG-TERM CARE; RISK ASSESSMENT; STRESS DISORDERS, POST-TRAUMATIC;

EID: 14844286535     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Panic Disorder. Am J Psychiatry 1998;155(suppl 5):1-34
2. Bruce SE, Vasile RG, Goisman RM, et al. Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia? Am J Psychiatry 2003;160:1432-1438
3. Stahl SM. Don't ask, don't tell, but benzodiazepines are still the leading treatments for anxiety disorder [BRAINSTORMS]. J Clin Psychiatry 2002;63:756-757
4. Scott EL, Pollack MH, Otto MW, et al. Clinician response to treatment refractory panic disorder: a survey of psychiatrists. J Nerv Ment Dis 1999; 187:755-757
5. Tesar GE, Rosenbaum JF, Pollack MH, et al. Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder. J Clin Psychiatry 1991;52:69-76
6. Rickels K, Downing R, Schweizer E, et al. Antidepressants for the treatment of generalized anxiety disorder: a placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 1993;50:884-895
7. Schweizer E, Pohl R, Balon R, et al. Lorazepam vs alprazolam in the treatment of panic disorder. Pharmacopsychiatry 1990;23:90-93
8. Noyes R Jr, Burrows GD, Reich JH, et al. Diazepam versus alprazolam for the treatment of panic disorder. J Clin Psychiatry 1996;57:349-355
9. Klein E. The role of extended-release benzodiazepines in the treatment of anxiety: a risk-benefit evaluation with a focus on extended-release alprazolam. J Clin Psychiatry 2002;63(suppl 14):27-33
10. Soumerai SB, Simoni-Wastila L, Singer C, et al. Lack of relationship between long-term use of benzodiazepines and escalation to high dosages. Psychiatr Serv 2003;54:1006-1011
11. Nagy LM, Krystal JH, Woods SW, et al. Clinical and medication outcome after short-term alprazolam and behavioral group treatment in panic disorder: 2.5 year naturalistic follow-up study. Arch Gen Psychiatry 1989;46:993-999
12. Pollack MH, Otto MW, Tesar GE, et al. Long-term outcome after acute treatment with alprazolam or clonazepam for panic disorder. J Clin Psychopharmacol 1993;13:257-263
13. Worthington JJ III, Pollack MH, Otto MW, et al. Long-term experience with clonazepam in patients with a primary diagnosis of panic disorder. Psychopharmacol Bull 1998;34:199-205
14. Greenblatt DJ, Shader RI, Abemethy DR. Drug therapy: current status of benzodiazepines, pt 2. N Engl J Med 1983;309:410-416
15. Greenblatt DJ, Shader RI, Abemethy DR. Drug therapy: current status of benzodiazepines, pt 1. N Engl J Med 1983;309:354-358
16. Hawkridge SM, Stein DJ. A risk-benefit assessment of pharmacotherapy for anxiety disorders in children and adolescents. Drug Saf 1998;19: 283-297
17. Rosenbaum JF, Woods SW, Groves JE, et al. Emergence of hostility during alprazolam treatment. Am J Psychiatry 1984;141:792-793
18. Pecknold JC, Swinson RP, Kuch K, et al. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial, 3: discontinuation effects. Arch Gen Psychiatry 1988;45:429-436
19. Ciraulo DA, Barnhill JG, Greenblatt DJ, et al. Abuse liability and clinical pharmacokinetics of alprazolam in alcoholic men. J Clin Psychiatry 1988; 49:333-337
20. Kan CC, Hilberink SR, Breteler MH. Determination of the main risk factors for benzodiazepine dependence using a multivariate and multidimensional approach. Compr Psychiatry 2004;45:88-94
21. Gaudreault P, Guay J, Thivierge RL, et al. Benzodiazepine poisoning: clinical and pharmacological considerations and treatment. Drug Saf 1991;6:247-265
22. Carson WH, Kitagawa H. Drug development for anxiety disorders: new roles for atypical antipsychotics. Psychopharmacol Bull 2004;38:38-45
23. Ray WA, Thapa PB, Gideon P. Benzodiazepines and the risk of falls in nursing home residents. J Am Geriatr Soc 2000;48:682-685
24. Gelpin E, Bonne O, Peri T, et al. Treatment of recent trauma survivors with benzodiazepines: a prospective study. J Clin Psychiatry 1996;57: 390-394
25. Mellman TA, Bustamante V, David D, et al. Hypnotic medication in the aftermath of trauma [letter]. J Clin Psychiatry 2002;63:1183-1184
26. Barker MJ, Greenwood KM, Jackson M, et al. Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs 2004;18:37-48
27. Deckersbach T. Effects of panic disorder and benzodiazepines on memory [dissertation]. Marburg, Germany: Philipps University; 1999
28. Lucki I, Rickels K, Geller AM. Chronic use of benzodiazepines and psychomotor and cognitive test performance. Psychopharmacology (Berl) 1986;88:426-433
29. Cowley DS, Roy-Byrne PP, Radant A, et al. Benzodiazepine sensitivity in panic disorder, effects of chronic alprazolam treatment. Neuropsychopharmacology 1995;12:147-157
30. Golombok S, Moodley P, Lader M. Cognitive impairment in long-term benzodiazepine users. Psychol Med 1988;18:365-374
31. Nemeroff CB. Anxiolytics: past, present, and future agents. J Clin Psychiatry 2003;64(suppl 3):3-6
32. Davidson JRT, DuPont RL, Hedges D, et al. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry 1999;60:528-535
33. Sramek JJ, Tansman M, Suri A, et al. Efficacy of buspirone in generalized anxiety disorder with coexisting mild depressive symptoms. J Clin Psychiatry 1996;57:287-291
34. Lang AJ. Treating generalized anxiety disorder with cognitive-behavioral therapy. J Clin Psychiatry 2004;65(suppl 13):14-19
35. States JH, St Dennis CD. Chronic sleep disruption and the reexperiencing cluster of posttraumatic stress disorder symptoms are improved by olanzapine: brief review of the literature and a case-based series. Primary Care Companion J Clin Psychiatry 2003;5:74-79
36. Bartzokis G, Freeman T, Roca V. Risperidone for patients with chronic combat-related PTSD. Presented at the 154th annual meeting of the American Psychiatric Association; May 5-10, 2001; New Orleans, La
37. Pitman RK, Sanders KM, Zusman RM, et al. Pilot study of secondary prevention of posttraumatic stress disorder with propranolol. Biol Psychiatry 2002;51:189-192
38. Raskind MA, Peskind ER, Kanter ED, et al. Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. Am J Psychiatry 2003;160:371-373
39. Pande AC, Davidson JR, Jefferson JW, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 1999;19:341-348
40. Pande AC, Pollack MH, Crockatt J, et al. Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 2000;20:467-471
41. Hertzberg MA, Butterfield MI, Feldman ME, et al. A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol Psychiatry 1999;45:1226-1229
42. Yehuda R, Yang RK, Golier JA, et al. Effect of topiramate on glucocorticoid receptor mediated action. Neuropsychopharmacology 2004;29:433-439
43. Berlant J, van Kammen DP. Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder, a preliminary report. J Clin Psychiatry 2002;63:15-20
44. Rickels K, Van Ameringen M, Snyder H, et al. Tiagabine in generalized anxiety disorder: a double-blind randomized controlled trial. Presented at the 43rd annual meeting of the American College of Neuropsychopharmacology (ACNP); Dec 12-16, 2004; San Juan, Puerto Rico
45. Simon NM, Worthington JJ, Doyle AC, et al. An open-label study of levetiracetam for the treatment of social anxiety disorder. J Clin Psychiatry 2004;65:1219-1222
46. Feltner DE, Crockatt JG, Dubovsky SJ, et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 2003;23: 240-249
47. Pande AC, Feltner DE, Jefferson JW, et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder, a placebo-controlled, multicenter study. J Clin Psychopharmacol 2004;24:141-149
48. Van Ameringen M, Mancini C, Pipe B, et al. Antiepileptic drugs in the treatment of anxiety disorders: role in therapy. Drugs 2004;64:2199-2220
49. Pollack MH, Worthington JJ, Manfro GG, et al. Abecamil for the treatment of generalized anxiety disorder: a placebo-controlled comparison of two dosage ranges of abecamil and buspirone. J Clin Psychiatry 1997; 58(suppl 11):19-23
50. Gorman JM. New molecular targets for antianxiety interventions. J Clin Psychiatry 2003;64(suppl 3):28-35
51. Gross C, Zhuang X, Stark K, et al. Serotonin1 A receptor acts during development to establish normal anxiety-like behaviour in the adult. Nature 2002;416:396-400
52. Zorrilla EP, Koob GF. The therapeutic potential of CRF1 antagonists for anxiety. Expert Opin Investig Drugs 2004;13:799-828
53. 1 receptor. J Clin Psychiatry 2002;63(suppl 11):6-10
54. Palucha A, Tatarczynska E, Branski P, et al. Group III mGlu receptor agonists produce anxiolytic- and antidepressant-like effects after central administration in rats. Neuropharmacology 2004;46:151-159